Therapeutics Acquisition Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities.
Cash Flow
| Q2 2020 | -18.00K | 0 | 82.69K |
|---|---|---|---|
| Q1 2021 | -395.02K | 0 | 0 |
| Q2 2021 | -16.83M | -5.85M | 285.87M |
RACA Cash Flow Statement (Q2 2020 – Q2 2021)
| Q2 2021 | Q1 2021 | Q2 2020 | |
|---|---|---|---|
Cash at beginning of period | 699.53K | 1.09M | 0 |
Operating activities | |||
Net income | -14.58M | -1.39M | -19.36K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 0 | 0 | 0 |
Stock-based compensation expense | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 |
Accounts payable | 0 | 347.63K | 1.36K |
Cash generated by operating activities | -16.83M | -395.02K | -18.00K |
Investing activities | |||
Purchases Of Investments | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 |
Cash generated by investing activities | -5.85M | 0 | 0 |
Financing activities | |||
Common Stock Issued | 0 | 0 | 25K |
Payments for dividends | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 |
Cash used in financing activities | 285.87M | 0 | 82.69K |
Net Change In Cash | 263.19M | -395.02K | 64.69K |
Cash at end of period | 263.88M | 699.53K | 64.69K |
| Data source | Data source | Data source |